[Federal Register Volume 77, Number 31 (Wednesday, February 15, 2012)]
[Notices]
[Pages 8885-8886]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2012-3549]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2011-D-0611]
Draft Guidance for Industry on Biosimilars: Questions and Answers
Regarding Implementation of the Biologics Price Competition and
Innovation Act of 2009; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of a draft guidance for industry entitled ``Biosimilars:
Questions and Answers Regarding Implementation of the Biologics Price
Competition and Innovation Act of 2009.'' This draft guidance is
intended to provide answers to common questions from sponsors
interested in developing proposed biosimilar products, biologics
license application (BLA) holders, and other interested parties
regarding FDA's interpretation of the Biologics Price Competition and
Innovation Act of 2009 (BPCI Act).
DATES: Although you can comment on any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that the Agency considers your comment on this
draft guidance before it begins work on the final version of the
guidance, submit either electronic or written comments on the draft
guidance by April 16, 2012. Submit either electronic or written
comments on the proposed collection of information by April 16, 2012.
ADDRESSES: Submit written requests for single copies of the draft
guidance to the Division of Drug Information, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 2201, Silver Spring, MD 20993-0002; or
the Office of Communication, Outreach and Development (HFM-40), Center
for Biologics Evaluation and Research, Food and Drug Administration,
1401 Rockville Pike, Suite 200N, Rockville, MD 20852-1448. Send one
self-addressed adhesive label to assist the office in processing your
requests. See the SUPPLEMENTARY INFORMATION section for electronic
access to the draft guidance document.
Submit electronic comments on the draft guidance to http://www.regulations.gov. Submit written comments to the Division of Dockets
Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.
[[Page 8886]]
FOR FURTHER INFORMATION CONTACT: Sandra Benton, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 6340, Silver Spring, MD 20993-0002, 301-
796-1042; or Stephen Ripley, Center for Biologics Evaluation and
Research (HFM-17), Food and Drug Administration, 1401 Rockville Pike,
Suite 200N, Rockville, MD 20852-1448, 301-827-6210.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of a draft guidance for industry
entitled ``Biosimilars: Questions and Answers Regarding Implementation
of the Biologics Price Competition and Innovation Act of 2009.'' This
draft guidance provides answers to common questions from sponsors
interested in developing proposed biosimilar products, BLA holders, and
other interested parties regarding FDA's interpretation of the BPCI
Act.
The BPCI Act, enacted as part of the Patient Protection and
Affordable Care Act (Pub. L. 111-148) on March 23, 2010, created an
abbreviated licensure pathway under section 351(k) of the Public Health
Service Act (42 U.S.C. 262(k)) for biological products demonstrated to
be biosimilar to, or interchangeable with, an FDA-licensed biological
reference product. This draft guidance describes FDA's current
interpretation of certain statutory requirements added by the BPCI Act
and includes questions and answers (Q&As) in the following categories:
Biosimilarity or Interchangeability
Provisions Related to Requirement to Submit a BLA for a
``Biological Product''
Exclusivity
The Q&A format is intended to promote transparency and facilitate
development programs for proposed biosimilar products by addressing
questions that may arise in the early stages of development. In
addition, these Q&As respond to questions the Agency has received from
prospective BLA and new drug application (NDA) applicants regarding the
appropriate statutory authority under which certain products will be
regulated.
FDA intends to update this guidance to include additional Q&As as
appropriate and intends to post information by Q&A number on FDA's Web
site regarding the publication date of draft guidance Q&As for comment,
the comment period, and the publication date of final guidance Q&As.
This draft guidance is being issued consistent with FDA's good
guidance practices regulation (21 CFR 10.115). The draft guidance, when
finalized, will represent the Agency's current thinking on this topic.
It does not create or confer any rights for or on any person and does
not operate to bind FDA or the public. An alternative approach may be
used if such approach satisfies the requirements of the applicable
statutes and regulations.
II. Comments
Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) either electronic or written comments regarding this
document. It is only necessary to send one set of comments. Identify
comments with the docket number found in brackets in the heading of
this document. Received comments may be seen in the Division of Dockets
Management between 9 a.m. and 4 p.m., Monday through Friday.
III. The Paperwork Reduction Act
This draft guidance describes information collection provisions
that are subject to review by the Office of Management and Budget (OMB)
under the Paperwork Reduction Act (the PRA) (44 U.S.C. 3501-3520). In
particular, the draft guidance refers to information collections
related to the submission of a 351(k) application. In accordance with
the PRA, FDA is soliciting public comment, in a separate document
published elsewhere in this issue of the Federal Register (see ``Agency
Information Collection Activities; Proposed Collection; Comment
Request; General Licensing Provisions; Section 351(k) Biosimilar
Applications'') on the information collection associated with the
submission of a 351(k) application. FDA will also seek OMB approval for
this information collection.
In addition, this draft guidance references other information
collections that are already approved by OMB and are not expected to
change as a result of the draft guidance. This includes information
collections related to the submission of (1) an investigational NDA,
which is covered under 21 CFR part 312 and approved under OMB control
number 0910-0014; (2) an NDA, which is covered under 21 CFR 314.50 and
approved under OMB control number 0910-0001; (3) a biologics license
application, which is covered under 21 CFR part 601 and approved under
OMB control number 0910-0338; and (4) labeling, which is covered under
21 CFR 201.57 and approved under OMB control number 0910-0572.
The draft guidance also discusses the retention of reserve samples
of the biological products used in comparative clinical pharmacokinetic
and/or pharmacodynamic studies intended to support a proposed 351(k)
application. Such reserve samples are samples of products or other
physical objects exempt under 5 CFR 1320.3(h)(2), and thus not
considered ``information'' as that term is defined under the PRA.
IV. Electronic Access
Persons with access to the Internet may obtain the document at
either http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm, http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/default.htm, or http://www.regulations.gov.
Dated: February 9, 2012.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2012-3549 Filed 2-14-12; 8:45 am]
BILLING CODE 4160-01-P